Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer

AIM: Some retrospective studies have shown a lack of benefit of 5‐fluorouracil (5‐FU) adjuvant chemotherapy in patients with mismatch repair (MMR) deficient colorectal cancer. Our aim was to assess if this molecular marker can predict benefit from 5‐FU adjuvant chemotherapy. A second objective was t...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Jover, R, Zapater, P, Castells, A, Llor, X, Andreu, M, Cubiella, J, Piñol, V, Xicola, R M, Bujanda, L, Reñé, J M, Clofent, J, Bessa, X, Morillas, J D, Nicolás‐Pérez, D, Payá, A, Alenda, C
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2006
Teme:
Colorectal Cancer
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC1856227/
https://ncbi.nlm.nih.gov/pubmed/16299036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2005.073015
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki